Find An Attorney
Word Document Print This Page Email This Page
Back to Biography Main »
Steve Parker
Partner
Northern Virginia
tel: +1 703.720.7006
fax: +1 703.720.7399

Steve.Parker@aporter.com
Download vCard

Practice Focus

Steve Parker concentrates his practice on transactions for life sciences companies, including patent licensing, partnerships and joint ventures; collaborative and joint research and development and related agreements; product acquisitions and dispositions; marketing, distribution, co-marketing and co-promotion agreements; manufacturing agreements; database agreements and issues; and a wide variety of matters relating to clinical trials and product development. He also has extensive corporate experience, including mergers and acquisitions, investment agreements, employment agreements and related matters, and corporate governance matters.

Mr. Parker's clients include pharmaceutical companies, public and private biotech, medical device and medical technology companies; nonprofit research institutes; universities; and angel and venture capital investors.

Mr. Parker has represented pharmaceutical companies since the late 1980s, and started in biotech in 1992 when he worked with Dr. Craig Venter to form The Institute for Genomic Research (TIGR) and worked on its foundational collaborations with, among others, Human Genome Sciences, (then) SmithKline Beecham, and Celera Genomics.

Mr. Parker has represented clients in matters throughout North America, including in Maryland, Boston, Northern California, San Diego, Boulder, and Research Triangle Park; throughout Europe; and in Japan, China, and India.

Prior to joining Arnold & Porter LLP, Mr. Parker served as a law clerk for Judge Frank M. Johnson, Jr., US Court of Appeals for the Eleventh Circuit (1982-1983).

Representative Matters

  • American Association of Blood Banks, in licensing and other transactional matters
  • ArQule, in licenses and related agreements with Hoffmann-La Roche, Pfizer, and other partners; in its acquisition of Cyclis Pharmaceuticals and other business combination transactions; and in clinical trial matters
  • AstraZeneca, in various matters, including preclinical collaboration agreements and licenses to clinical compounds
  • AtheroGenics, in its license to AstraZeneca (cited as the biggest biotech deal of 2005 by Bio World) and with (then) Fujisawa
  • Avalon Pharmaceuticals, in clinical trial matters
  • Center for Health Outcomes Research, in research collaborations with pharmaceutical and biotech companies, and other life sciences organizations
  • EntreMed, in acquisitions and licensing matters
  • Gabriel Sciences, in licensing and intellectual property (IP) transactional matters
  • Gene Logic, in collaborations with partners, including Eli Lilly
  • Gilead Sciences, in various licensing and collaboration matters, including with Japan Tobacco, Chiron, Achillion Pharmaceuticals, Genelabs, The Scripps Research Institute, and 4AZA Biosciences, and in its US$525 million purchase of royalty rights from Emory University
  • GlaxoSmithKline, in licensing matters
  • The Halifax Group, in in-licensing and IP issues associated with an acquisition
  • Inflazyme, in its acquisition of GlycoDesign
  • MacroGenics, in licensing and other collaborations, including with Genzyme; in its acquisition of Raven Biotechnologies; and in clinical trial agreements
  • NED, Inc., in connection with its foundational agreements relating to its diagnostic technology
  • Noxilizer, in connection with the development and commercialization of its sterilization technology
  • Pharma-Pen, in its sale to West Pharmaceuticals
  • Plethora Solutions, in its acquisition of a medical device company from Endocare
  • RegeneRx, in licensing and other collaboration matters
  • Sanofi-Aventis, in licensing matters
  • Sciele Pharma, in licensing matters, including with Galephar Pharmaceutical Research and Novo Nordisk
  • Sequella, in connection with European collaboration agreements and other collaborations
  • Steba Biotech, in licensing and related matters
  • Sucampo Pharmaceuticals, in a license to Abbott Laboratories
  • Symphogen, in a cross-license with Cambridge Antibody Technology
  • Touro College, in life sciences matters, including the establishment of a life sciences incubator
  • University of Pittsburgh Medical Center, in a partnership on vaccine development and production with a medical device manufacturer
  • VIRxSYS, in licensing and acquisition matters, including its acquisition of Intronn
  • Wave Inc., an early stage biotech, in strategic planning and licensing matters
  • The Wellcome Trust, in transactional matters
  • Whatman PLC, in its acquisition of assets from Life Technologies
  • Several universities in life sciences matters, and clients in negotiating with dozens of different universities around the world, in connection with research and other collaboration agreements
  • Extensive experience representing nonprofits, including TIGR, the American Red Cross, the American Association of Blood Banks, and The Scripps Research Institute
  • A wide variety of matters for several large pharmaceutical companies and specialty pharmaceutical companies, including licenses, marketing and distribution agreements, collaborations, strategic counseling and transactional counseling

Representative Matters

  • American Association of Blood Banks, in licensing and other transactional matters
  • ArQule, in licenses and related agreements with Hoffmann-La Roche, Pfizer, and other partners; in its acquisition of Cyclis Pharmaceuticals and other business combination transactions; and in clinical trial matters
  • AstraZeneca, in various matters, including preclinical collaboration agreements and licenses to clinical compounds
  • AtheroGenics, in its license to AstraZeneca (cited as the biggest biotech deal of 2005 by Bio World) and with (then) Fujisawa
  • Avalon Pharmaceuticals, in clinical trial matters
  • Center for Health Outcomes Research, in research collaborations with pharmaceutical and biotech companies, and other life sciences organizations
  • EntreMed, in acquisitions and licensing matters
  • Gabriel Sciences, in licensing and intellectual property (IP) transactional matters
  • Gene Logic, in collaborations with partners, including Eli Lilly
  • Gilead Sciences, in various licensing and collaboration matters, including with Japan Tobacco, Chiron, Achillion Pharmaceuticals, Genelabs, The Scripps Research Institute, and 4AZA Biosciences, and in its US$525 million purchase of royalty rights from Emory University
  • GlaxoSmithKline, in licensing matters
  • The Halifax Group, in in-licensing and IP issues associated with an acquisition
  • Inflazyme, in its acquisition of GlycoDesign
  • MacroGenics, in licensing and other collaborations, including with Genzyme; in its acquisition of Raven Biotechnologies; and in clinical trial agreements
  • NED, Inc., in connection with its foundational agreements relating to its diagnostic technology
  • Noxilizer, in connection with the development and commercialization of its sterilization technology
  • Pharma-Pen, in its sale to West Pharmaceuticals
  • Plethora Solutions, in its acquisition of a medical device company from Endocare
  • RegeneRx, in licensing and other collaboration matters
  • Sanofi-Aventis, in licensing matters
  • Sciele Pharma, in licensing matters, including with Galephar Pharmaceutical Research and Novo Nordisk
  • Sequella, in connection with European collaboration agreements and other collaborations
  • Steba Biotech, in licensing and related matters
  • Sucampo Pharmaceuticals, in a license to Abbott Laboratories
  • Symphogen, in a cross-license with Cambridge Antibody Technology
  • Touro College, in life sciences matters, including the establishment of a life sciences incubator
  • University of Pittsburgh Medical Center, in a partnership on vaccine development and production with a medical device manufacturer
  • VIRxSYS, in licensing and acquisition matters, including its acquisition of Intronn
  • Wave Inc., an early stage biotech, in strategic planning and licensing matters
  • The Wellcome Trust, in transactional matters
  • Whatman PLC, in its acquisition of assets from Life Technologies
  • Several universities in life sciences matters, and clients in negotiating with dozens of different universities around the world, in connection with research and other collaboration agreements
  • Extensive experience representing nonprofits, including TIGR, the American Red Cross, the American Association of Blood Banks, and The Scripps Research Institute
  • A wide variety of matters for several large pharmaceutical companies and specialty pharmaceutical companies, including licenses, marketing and distribution agreements, collaborations, strategic counseling and transactional counseling

Rankings

Chambers USA: America's Leading Lawyers for Business 2010 for Life Sciences: Commercial (National) and Intellectual Property (Northern Virginia) ("Steve Parker is highly praised for his patent licensing, partnerships and joint venture work.")

Chambers Global: The World's Leading Lawyers for Business 2010 for Life Sciences: Commercial (Globally) ("Steve Parker focuses on corporate transactions featuring pharmaceutical companies" and is hailed as one of two "superstars".)

Washington Business Journal's "Top Washington Lawyers" 2009: Winner for Technology Transactions

Chambers Global: The World's Leading Lawyers for Business 2009 for Life Sciences ("widespread market praise for his broad life sciences skills, which encompass M&A, joint ventures, patent licensing and corporate governance")

Chambers USA: America's Leading Lawyers for Business 2009 for Life Sciences: Commercial (National) and Intellectual Property (Northern Virginia) ("Acts on a number of transactional and licensing matters, particularly on behalf of pharmaceutical companies. Sources appreciate his analytical approach.")

Practical Law Company's Which lawyer? Yearbook 2009: Highly recommended for Life Sciences: Commercial and Partnering ("Prominent DC-based practitioner who has enjoyed a particularly active year with extensive experience of corporate finance, partnering and IP licensing issues.")

Practical Law Company's Which lawyer? Yearbook 2009: Recommended for Corporate/M&A ("Expert assisting life sciences in managing M&A and all related corporate matters of regulation and distribution.")

Chambers USA: America's Leading Lawyers for Business 2008 for Life Sciences (National) and Intellectual Property (Northern Virginia) ("Steve Parker 'has a heavyweight nationwide presence, fully deserves his stellar reputation and is a fantastic guy, to boot.' He is especially lauded for his transactional work, and has worked on complex licensing matters, corporate governance and M&A matters." "Sources compliment his licensing and corporate due diligence work, describing him as 'phenomenally nice to work with, he has a keen ability to understand things from his clients' perspective.'")

Practical Law Company's Which lawyer? Yearbook 2008: Highly recommended for Life Sciences: Commercial and Partnering

Chambers USA: America's Leading Lawyers for Business 2007 for Life Sciences (National) ("Steve Parker is the 'first port of call for all issues thanks to his astounding breadth of knowledge,' say clients. Specializing in transactions, including licensing, M&A, technology transfers and collaborations, he has 'never let down a client and can be relied on without a shadow of a doubt,' according to interviewees.")

Practical Law Company's Cross-Border Competition Law Handbook 2007 for Mergers & Acquisitions

Practical Law Company's Which lawyer? Yearbook 2007: Recommended for Corporate/M&A

Practical Law Company's Which lawyer? Yearbook 2007: Highly recommended for IT and E-commerce

Advisories

PDF "Healthcare Reform--New Tax Credit Available to Small Biotechs Prepared to Act Promptly." (PDF: 274 kB) Apr 2010.
Practice Areas
Corporate and Securities »
Intellectual Property »
Technology / IP Transactions and Licensing »
Education
JD, Cornell University, 1982
BA, Dartmouth College, 1978
Admissions
District of Columbia
Virginia